Actividad antidiabética de un extracto de hexane de Prosthechea michuacana en ratas diabéticas inducidas por estreptozotocina

En este estudio se determinaron los efectos antidiabéticos, antihiperlipidemico y glicación (AGEs) de algunos extractos de Prosthechea michuacana (PM) en ratas normoglucémicas y con diabetes inducida por estreptozotocina (STZ). Se probó el efecto de los extractos de hexano, cloroformo, metanol de PM sobre la actividad hipoglucemiante, la carga de glucosa, los parámetros bioquímicos tales como triglicéridos, niveles de colesterol total, peroxidación lipídica, glucógeno del hígado, los niveles de glucógeno muscular, niveles de superoxide dismutase, catalasa, glutation reductasa and glutation peroxidasa en ratas normales y diabéticas. También se determinó la glucosa 6 Phosphatasa y las actividades de GK en el hígado, la inhibición de la insulina y la glicosilación de las proteínas. Los niveles de glucosa sanguínea se determinaron por el método de GOD-POD. La administración de los extractos de cloroformo y metanol no presentaron ningún efecto sobre la SD, en cambio el tratamiento con el extracto de hexano (PM) a dosis de 200 y 400 mg/kg, inhibió la diabetes y sus complicaciones. Ambas dosis redujeron significativamente los niveles de glucosa sanguínea (35.75 y 47.78% en las ratas diabéticas, 50.64 y 57.10% en las ratas diabéticas), el aumento de la glucogénesis y la disminución de la gluconeogénesis conduce el metabolismo de la glucosa hacia la normalidad. Estas dosis disminuyeron la hiperlipidemia reduciendo el colesterol (41.56%, 46.08%) y los triglicéridos (37.5%, 46.27%) así como también mejoran las actividades antioxidantes de las enzimas hepáticas. Su efecto se comparó con la glibenclamida y tolbutamida, fármacos usados como antidiabeticos. El extracto de hexano disminuyo la hiperinsulinemia en un 24% en SD. PM mostró un cambio significativo in vitro sobre la formación de los AGEs con valores de IC50 de 48.3 mg/ml comparable al efecto inhibidor de la aminoguanidina con valores de IC50 de 27.2 mg/ml. Se redujo en las ratas con diabetes crónica los niveles de HbA1C en un 6.4%. Por lo que se concluye que el extracto hexánico de los bulbos de Prosthechea michuacana posee actividad anti-hiperglucémica, antihiperlipemica, mejora la hiperinsulinemia mostrando un cambio significativo en la formación de AGEs, lo que puede llegar a ser de importancia en el tratamiento de la diabetes y sus complicaciones

Gut Microbiota and Endothelial Dysfunction Markers in Obese Mexican Children and Adolescents

Obesity is a metabolic disease characterized by low-grade inflammation and accompanied by dyslipidemia and up-regulation of other bioactive molecules, creating a predisposition to endothelial dysfunction and metabolic syndrome. We studied the association between gut microbiota diversity and endothelial dysfunction (EDF) markers in obese Mexican children and adolescents. We examined clinical data including metabolic factors and EDF markers in blood samples. Gut bacterial diversity was characterized by high-throughput sequencing of V3-16S rDNA libraries. Triglycerides, insulin, homeostasis model assessment-insulin resistant (HOMA-IR), leptin, C-reactive protein (CRP), and EDF marker intercellular adhesion molecule 1 (ICAM-1) were significantly higher in obese children and adolescents. Multivariate analysis showed statistically significant positive associations between vascular cell adhesion molecule 1 (VCAM-1) and Veillonellaceae, and between ICAM-1 and Ruminococcus in obese children. In obese adolescents, there was a statistically significant positive association between total cholesterol and Ruminococcus, and between ICAM-1 and Bacteroides. LEfSe analysis showed that the genus Lactobacillus and family Coriobacteriaceae were enriched in children, and genera Collinsella and Prevotella were enriched in obese adolescents. Obese children and adolescents had higher levels of insulin resistance and metabolic syndrome. These results suggest that obese Mexican children and adolescents had increased levels of CRP and a reduction of adiponectin, which causes higher expression of EDF markers, affecting endothelial function and associating with changes in the gut microbiota

Favipiravir and/or nitazoxanide: a randomized, double-blind, 2x2 design, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE)

BackgroundThe 2020 pandemic of SARS-CoV-2 causing COVID-19 disease is an unprecedented global emergency. COVID-19 appears to be a disease with an early phase where the virus replicates, coinciding with the first presentation of symptoms, followed by a later 'inflammatory' phase which results in severe disease in some individuals. It is known from other rapidly progressive infections such as sepsis and influenza that early treatment with antimicrobials is associated with a better outcome. The hypothesis is that this holds for COVID-19 and that early antiviral treatment may prevent progression to the later phase of the disease.MethodsTrial design: Phase IIA randomised, double-blind, 2 × 2 design, placebo-controlled, interventional trial.RandomisationParticipants will be randomised 1:1 by stratification, with the following factors: gender, obesity, symptomatic or asymptomatic, current smoking status presence or absence of comorbidity, and if the participant has or has not been vaccinated.BlindingParticipants and investigators will both be blinded to treatment allocation (double-blind).DiscussionWe propose to conduct a proof-of-principle placebo-controlled clinical trial of favipiravir plus or minus nitazoxanide in health workers, their household members and patients treated at the Mexican Social Security Institute (IMSS) facilities. Participants with or without symptomatic COVID-19 or who tested positive will be assigned to receive favipiravir plus nitazoxanide or favipiravir plus nitazoxanide placebo. The primary outcome will be the difference in the amount of virus ('viral load') in the upper respiratory tract after 5 days of therapy. Secondary outcomes will include hospitalization, major morbidity and mortality, pharmacokinetics, and impact of antiviral therapy on viral genetic mutation rate. If favipiravir with nitazoxanide demonstrates important antiviral effects without significant toxicity, there will be a strong case for a larger trial in people at high risk of hospitalization or intensive care admission, for example older patients and/or those with comorbidities and with early disease.Trial registrationClinicalTrials.gov NCT04918927 . Registered on June 9, 2021